SG11201407425SA - Methods for inhibition of shc-1/p66 to combat aging-related diseases - Google Patents
Methods for inhibition of shc-1/p66 to combat aging-related diseasesInfo
- Publication number
- SG11201407425SA SG11201407425SA SG11201407425SA SG11201407425SA SG11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- taiwan
- shc
- dist
- east
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101100477498 Caenorhabditis elegans shc-1 gene Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 230000032683 aging Effects 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/727,387 US20140179774A1 (en) | 2012-12-26 | 2012-12-26 | Methods for inhibition of shc-1/p66 to combat aging-related diseases |
PCT/CN2013/075599 WO2014101366A1 (en) | 2012-12-26 | 2013-05-14 | Methods for inhibition of shc-1/p66 to combat aging-related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407425SA true SG11201407425SA (en) | 2014-12-30 |
Family
ID=50975338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407425SA SG11201407425SA (en) | 2012-12-26 | 2013-05-14 | Methods for inhibition of shc-1/p66 to combat aging-related diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140179774A1 (de) |
EP (1) | EP2838528A4 (de) |
JP (1) | JP6305422B2 (de) |
KR (2) | KR20170027860A (de) |
CN (1) | CN104487069A (de) |
IN (1) | IN2014MN02382A (de) |
SG (1) | SG11201407425SA (de) |
WO (1) | WO2014101366A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018026442A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Small molecule inhibition for preventing or treating fibrotic diseases |
CN113874056B (zh) | 2019-05-30 | 2023-12-15 | 贝克顿·迪金森公司 | 用于药物递送装置的药筒适配器 |
KR20230083169A (ko) | 2021-12-02 | 2023-06-09 | 대주전자재료 주식회사 | 다공성 규소-탄소 복합체, 이의 제조방법 및 이를 포함하는 음극 활물질 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09291039A (ja) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | プロシアニジンを有効成分とする抗肥満剤 |
DK0815857T3 (da) | 1995-12-26 | 2005-01-24 | Suntory Ltd | Anti-adipöst middel indeholdende procyanidin som den aktive ingrediens |
GB9906515D0 (en) * | 1999-03-22 | 1999-05-19 | Europ I Of Oncology | Materials and methods relating to the effects oF P66 expression |
WO2000078326A1 (en) | 1999-06-18 | 2000-12-28 | Dry Creek Nutrition, Inc. | Method and composition for preventing or treating adverse physiological effects associated with cardiac disease |
KR100509119B1 (ko) * | 1999-07-16 | 2005-08-18 | 주식회사 엘지생활건강 | 프로시아니딘 올리고머를 유효성분으로 하는 약제 |
NZ528322A (en) * | 2001-03-15 | 2005-03-24 | Proteotech Inc | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's |
EP1256335A1 (de) | 2001-05-10 | 2002-11-13 | Cognis France S.A. | Verwendung von oligomeren Procyanolidinen |
CN1443533A (zh) * | 2002-03-07 | 2003-09-24 | 程彦杰 | 原花青素类化合物在用于制备解酒保肝产品方面的用途 |
KR100531472B1 (ko) * | 2002-08-09 | 2005-11-28 | 주식회사 이롬 | 항산화 활성을 가지는 찔레나무 추출물을 포함하는 화장품 조성물 및 상기 추출물의 제조방법 |
JP2006232670A (ja) * | 2003-05-20 | 2006-09-07 | Ajinomoto Co Inc | 神経障害用薬剤 |
JP2005097273A (ja) * | 2003-08-19 | 2005-04-14 | Toyo Shinyaku:Kk | 運動能力向上組成物 |
JPWO2005030200A1 (ja) * | 2003-09-26 | 2006-12-07 | 麒麟麦酒株式会社 | 自己免疫疾患治療剤 |
CN100586431C (zh) | 2007-09-28 | 2010-02-03 | 天津市尖峰天然产物研究开发有限公司 | 原花青素b2在制备防治糖尿病及血管并发症药物的应用 |
US20130123204A1 (en) * | 2008-12-31 | 2013-05-16 | Industrial Technology Research Institute | Method for treating hepatitis b |
TWI370736B (en) | 2008-12-31 | 2012-08-21 | Ind Tech Res Inst | Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus |
CN101822372A (zh) * | 2009-03-05 | 2010-09-08 | 财团法人工业技术研究院 | 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品 |
US20120095063A1 (en) * | 2009-04-17 | 2012-04-19 | Francisco Villareal | Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function |
TWI458487B (zh) | 2009-12-30 | 2014-11-01 | Ind Tech Res Inst | 藥學組合物之用途 |
JP2011178728A (ja) | 2010-03-02 | 2011-09-15 | Kobe Univ | Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品 |
NO2689777T3 (de) * | 2011-03-22 | 2018-08-25 | ||
WO2012163588A2 (en) | 2011-05-27 | 2012-12-06 | Unilever Plc | Anti-ageing composition |
US9187448B2 (en) * | 2011-08-05 | 2015-11-17 | Cardero Therapeutics, Inc. | Flavonoid compounds |
JP5813576B2 (ja) * | 2012-05-22 | 2015-11-17 | アピオン・ジャパン有限会社 | サーチュイン1(sirt1)遺伝子活性化剤 |
CN102688501A (zh) | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | 原花青素b2磷脂复合物及其制备方法和用途 |
CN102688230B (zh) | 2012-06-20 | 2014-12-03 | 浙江萧山医院 | 原花青素b2的用途 |
EP2917220A4 (de) * | 2012-11-08 | 2016-07-20 | Cellarouge Pty Ltd | Modifizierte polyphenole und modifizierte polyphenolzusammensetzungen |
-
2012
- 2012-12-26 US US13/727,387 patent/US20140179774A1/en not_active Abandoned
-
2013
- 2013-05-14 WO PCT/CN2013/075599 patent/WO2014101366A1/en active Application Filing
- 2013-05-14 EP EP13868008.7A patent/EP2838528A4/de active Pending
- 2013-05-14 SG SG11201407425SA patent/SG11201407425SA/en unknown
- 2013-05-14 CN CN201380029637.7A patent/CN104487069A/zh active Pending
- 2013-05-14 KR KR1020177005294A patent/KR20170027860A/ko not_active IP Right Cessation
- 2013-05-14 KR KR1020147033339A patent/KR20150013629A/ko active Search and Examination
- 2013-05-14 IN IN2382MUN2014 patent/IN2014MN02382A/en unknown
- 2013-05-14 JP JP2015544314A patent/JP6305422B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20150013629A (ko) | 2015-02-05 |
JP2016502532A (ja) | 2016-01-28 |
EP2838528A1 (de) | 2015-02-25 |
US20140179774A1 (en) | 2014-06-26 |
CN104487069A (zh) | 2015-04-01 |
KR20170027860A (ko) | 2017-03-10 |
WO2014101366A1 (en) | 2014-07-03 |
JP6305422B2 (ja) | 2018-04-04 |
IN2014MN02382A (de) | 2015-08-14 |
EP2838528A4 (de) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201407200TA (en) | Liquid formulation | |
SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201408261UA (en) | Syringe | |
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |